Elemental impurity testing is essential to deliver safe drug products to patients and is a regulatory requirement. It is important to assess the risk of elemental impurities from all sources in the manufacturing process, including process equipment, water, container/packaging, raw materials, drug substances, and the final drug product.
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Nate Edwards of Arya Consulting, Elisabeth Gardiner of Tevard Biosciences, and Donny Xu of the RTW Institute discuss global competition for rare disease therapies.
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, explains how capping is measured for mRNA synthesis and how upstream process design shapes downstream purity.
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, breaks down the company’s one-pot technology for mRNA synthesis, AMCAP, which won the CPHI Award for Manufacturing Excellence at CPHI Milan 2026.
The FDA grants accelerated approval to neladalkib for pretreated ALK-positive lung cancer, showing how next-gen kinase inhibitors tackle drug resistance
Robert Sciscento, a senior scientist at Alcami Corporation, discusses scaling up oral peptide products and what the future looks like for GLP-1 drug delivery.